Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Acquired Immune Deficiency Syndromes (1999)|July 21, 2001
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled studyL Ruiz, E Negredo, P Domingo, et al.
Journal of Human Hypertension|May 24, 2000
Usefulness of the I/D angiotensin-converting enzyme genotype for detecting the risk of left ventricular hypertrophy in pharmacologically treated hypertensive menJ López-Contreras, F Blanco-Vaca, X Borrás, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2000
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic responseR Paredes, T Puig, A Arnó, et al.
HIV Medicine|January 10, 2013
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB studyE Ribera, M Larrousse, A Curran, et al.
HIV Medicine|December 16, 2014
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratioE Martínez, E Ribera, B Clotet, et al.
HIV Medicine|March 28, 2008
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell countsE De Lazzari, A León, J A Arnaiz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 15, 2000
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapyA Tuldrà, C R Fumaz, M J Ferrer, et al.
HIV Medicine|January 15, 2014
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavirE Martinez, A Gonzalez-Cordon, E Ferrer, et al.
Antiviral Research|November 28, 2009
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study)P Echeverría, E Negredo, G Carosi, et al.
Antiviral Therapy|July 19, 2005
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-upE Negredo, R Paredes, A Bonjoch, et al.
Pageof 3